Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | 1.20% | |
| Oversold Stochastic | Weakness | 1.20% | |
| 180 Bearish Setup | Bearish Swing Setup | 4.69% | |
| Slingshot Bearish | Bearish Swing Setup | 4.69% | |
| NR7 | Range Contraction | 4.69% | |
| Narrow Range Bar | Range Contraction | 4.69% | |
| Lower Bollinger Band Walk | Weakness | 4.69% | |
| Multiple of Ten Bearish | Other | 4.69% | |
| Oversold Stochastic | Weakness | 4.69% | |
| Lower Bollinger Band Walk | Weakness | 4.74% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | 23 minutes ago |
| Fell Below Previous Day's Low | 23 minutes ago |
| Down 1% | 23 minutes ago |
| Up 1% | 23 minutes ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
Get a Trading Assistant
- Earnings date: 11/07/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer IBD 50 Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 248.16 |
| 52 Week Low | 126.9681 |
| Average Volume | 327,317 |
| 200-Day Moving Average | 174.48 |
| 50-Day Moving Average | 212.26 |
| 20-Day Moving Average | 202.51 |
| 10-Day Moving Average | 195.87 |
| Average True Range | 7.03 |
| RSI (14) | 39.76 |
| ADX | 28.35 |
| +DI | 21.77 |
| -DI | 34.10 |
| Chandelier Exit (Long, 3 ATRs) | 202.91 |
| Chandelier Exit (Short, 3 ATRs) | 205.58 |
| Upper Bollinger Bands | 220.68 |
| Lower Bollinger Band | 184.34 |
| Percent B (%b) | 0.27 |
| BandWidth | 17.95 |
| MACD Line | -6.80 |
| MACD Signal Line | -5.43 |
| MACD Histogram | -1.3736 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 203.98 | ||||
| Resistance 3 (R3) | 204.31 | 201.39 | 202.36 | ||
| Resistance 2 (R2) | 201.39 | 198.92 | 201.23 | 201.82 | |
| Resistance 1 (R1) | 197.83 | 197.39 | 196.37 | 197.50 | 201.28 |
| Pivot Point | 194.91 | 194.91 | 194.19 | 194.75 | 194.91 |
| Support 1 (S1) | 191.35 | 192.44 | 189.89 | 191.02 | 187.24 |
| Support 2 (S2) | 188.43 | 190.91 | 188.27 | 186.70 | |
| Support 3 (S3) | 184.87 | 188.43 | 186.16 | ||
| Support 4 (S4) | 184.54 |
